Patient Registry

This video explains the concept of the ERN eUROGEN registry for patients:

Until now, very limited data have been gathered on disease progression, surgical procedures, and treatment outcomes, and the few existing databases are not standardised, fragmenting and scattering the information. Moreover, long-term follow-up of treatment outcomes into adolescence and adulthood is lacking, hindering improvement over time.

The ERN eUROGEN registry has several objectives:

• The ERN eUROGEN registry will enable the identification of contemporary cohorts of patients with rare uro-recto-genital diseases for clinical research such as studies of diagnostic tools and prognostic biomarkers as well as interventional trials evaluating novel drugs and treatment protocols.
• The ERN eUROGEN registry will enable monitoring of diagnostic and treatment procedures at healthcare providers (HCPs), which is important because, for most rare uro-recto-genital diseases and complex conditions, no clear guidelines for these procedures are available.
• Finally, the ERN eUROGEN registry will enable research into the diagnosis, treatment and outcome or prognosis of rare uro-recto-genital diseases. It will help us to gain knowledge about the course of the diseases and the effect of different treatments.

The final ERN eUROGEN registry will benefit patients and their families who go through a diagnosis odyssey, physicians who will learn about rare and complex conditions and get new insights into the best treatment options, and scientists who are looking for patient cohorts for future research and clinical trials.

The Principal Investigators at Healthcare Providers (HCPs) involved in ERN eUROGEN as Full Members or Affiliated Partners will ensure that the implementation of the ERN eUROGEN registry complies with their HCPs’ rules and regulations. This may mean they need to apply for local approval for implementation of the ERN eUROGEN registry.

Participation in the ERN eUROGEN registry is also open to non-member/partner HCPs.

After obtaining ethical and legal approval, HCPs will begin prospectively including all new patients attending their centre for any ERN eUROGEN Expertise Area in which they are involved.

HCPs will also include patients who attended the HCP for an ERN eUROGEN Expertise Area for the first time between 2022 and now. A protocol is available to guide the retrospective patient inclusion process.
➡️ ERN eUROGEN Registry Retrospective Protocol (version 15 April 2026)

Only patients who provided (or whose parents/legal representatives provided) informed consent will be included in the ERN eUROGEN registry.
➡️ ERN eUROGEN Registry Patient Informed Consent Form

The ERN eUROGEN platform will be built on the collection of core data set elements and domain-specific elements for specific rare uro-recto-genital diseases. Thus, the registry will comprise the following sets of data:

1. The JRC common data set (CDE), defined by the EU RD Platform, has 16 data elements describing patients’ general health status. The CDE is common to all rare disease registries, serves as the connecting point for all ERN databases, and ensures that individuals are uniquely identified and not duplicated across different rare disease registries:
➡️ ERN eUROGEN Registry Common Data Elements (version 10 March 2022)

2. Uro-recto-genital “Clinical Practice Snapshots” initially consist of six clinical questions (around 10 data elements) per Expertise Area that describe the care pathway of patients in the first year after the start of treatment for the rare uro-recto-genital disease or complex condition. These data enable us to perform a snapshot of the current clinical practices in the EU. Clinical Practice Snapshots have been developed for the following Expertise Areas:

➡️ Bladder Exstrophy (EA 1.2) (version 21 August 2024)
➡️ Posterior Urethral Valves (EA 1.5) (version 30 April 2024)
➡️ Anorectal Malformations (EA 1.7) (version 15 January 2025)
➡️ Paediatric Kidney Transplantations (EA 1.8) (version 22 August 2022)
➡️ Complicated Pelvic Floor Disorders (EA 2.1) (version 9 November 2022)
➡️ Testicular Cancer (EA 3.2) (version 4 October 2023)
➡️ Adrenal Tumours (EA 3.3) (version 3 September 2024)

We are currently working on the Clinical Practice Snapshots for the other Expertise Areas.

3. In addition, the dataset will be expanded with clinical follow-up forms that will collect information on further treatments and outcomes. These are currently under development.

4. We will also send out Patient Reported Outcome Measures (PROM) questionnaires. There will be questionnaires about satisfaction with the care process (H-care survey) and about health-related quality of life (PedsQl questionnaire for patients from Workstream 1 and SF-36 or RAND-36 for patients from Workstream 2 and Workstream 3).

A short guide has been produced for the PROM questionnaires in the ERN eUROGEN registry, along with their current status as of September 2024:
➡️ ERN eUROGEN Registry Patient Reported Outcome Measure (PROM) Questionnaires Factsheet (version 24 February 2025)

Schematic overview of data collection in the ERN eUROGEN registry. Note that the shaded blue colours indicate who will fill out the information, and that parts of the Informed Consent forms and PROM questionnaires are filled out by either patients or their parents, depending on the patient’s age.

The data in the ERN eUROGEN Registry will be made Findable, Accessible, Interoperable, and Reusable for humans and computers (i.e., FAIR).

Frequently Asked Questions (FAQs)

➡️ ERN eUROGEN Registry – FAQ EA 1.5 Posterior Urethral Valves (version 1 May 2024)
➡️ ERN eUROGEN Registry – FAQ EA 1.7 Anorectal Malformations (version 11 September 2025)
➡️ ERN eUROGEN Registry – FAQ EA 2.1 AMS800 (version 25 April 2024)
➡️ ERN eUROGEN Registry – FAQ EA 3.3 Adrenal Tumours (version 6 October 2023)
➡️ ERN eUROGEN Registry – FAQ Common Data Elements (version 24 February 2025)

The ERN eUROGEN registry will be implemented in Castor using a Data Processing Agreement between Radboudumc and Castor. Only Healthcare Providers who have signed the Data Sharing Agreement will obtain access to the online registry. Access for authorised users to the online registry is controlled by assigning a secure, individualised password.
➡️ ERN eUROGEN Registry Data Sharing Agreement

Scientific Researchers, clinicians, patient organisations, policymakers, companies, etc., are invited to apply to use data from the ERN eUROGEN registry. The Data Access and Sharing Policy describes the data request process.
➡️ ERN eUROGEN Registry Data Access and Sharing Policy (version 24 February 2025)

Parmida Anvary, Radboudumc, Nijmegen, The Netherlands: Overview of surgical care for primary closure of Classic Bladder Exstrophy (2025-2027)

Parmida Anvary, a PhD student from Radboudumc in Nijmegen, the Netherlands, will conduct a study on classical bladder exstrophy. She will use the data from the ERN eUROGEN registry to create an overview of how the different centres participating in the ERN eUROGEN registry deliver surgical care for primary closure. This will allow her to clearly describe what primary closure entails at each individual centre. She will also create an overview of the different countries in general.

She will not only look at the type of primary closure but also focus on the pre-operation care, wound coverage if the closure is delayed, location of the closure surgery (to get an overview of the centralization of CBE care), types of immobilization post-operatively and the effect on bladder dehiscence, wound drainage after the primary closure, and reoperations for complications. Ideally, she wants to be able to conclude which operations have the best outcomes and implement those into a future guideline.

Yazan Rawasdeh, Aarhus University Hospital, Aarhus, Denmark: Improving Care for Children with Posterior Urethral Valves (2025)

In collaboration with experts from ERN eUROGEN, Associate Professor Yazan Rawashdeh from Aarhus University, Denmark, recently co-authored a Clinical Consensus Statement on the management of Posterior Urethral Valves (PUV). The next step for the expert team is to compare these consensus recommendations with current clinical practice across Europe. Using data from the ERN eUROGEN registry, the team will analyse the epidemiology, geographical distribution, procedure numbers, and management details of PUV cases. This work aims to identify areas where patient management can be improved and harmonized, ultimately enhancing outcomes for this rare patient group and guiding future research and collaboration efforts.

Reports

Reports comparing clinical practice among different Healthcare Providers have been generated:

2025:

• Common Data Elements
• Bladder Exstrophy
• Posterior Urethral Valves
• Anorectal Malformations
• Complicated & Complex Pelvic Floor Disorders treated with the AMS800 device
• Testicular Cancer
• Adrenal Tumours

2024:

• Common Data Elements
• Posterior Urethral Valves
• Anorectal Malformations
• Complicated & Complex Pelvic Floor Disorders treated with the AMS800 device
• Testicular Cancer
• Adrenal Tumours

2023:

• Common Data Elements
• Posterior Urethral Valves
• Anorectal Malformations
• Complicated & Complex Pelvic Floor Disorders treated with the AMS800 device
• Adrenal Tumours

PhD Thesis

Oomen, L. (2025) Optimizing pediatric kidney transplantation care. A regional, national, and international perspective. Thesis.

The PhD thesis of Loes Oomen, former ERN eUROGEN Clinical Data Specialist, shows some research options related to long-term registries.

The stakeholders of the ERN eUROGEN Registry are the groups in society who will be positively affected by ERN eUROGEN’s Registry outcome. These are:

1. Patients, their families, and patient organisations in the field of rare uro-recto-genital diseases: Patients will be the primary target group of the registry, which aims to improve their medical care through stringent performance and outcome monitoring, generate highly relevant prognostic information, and facilitate access to clinical trials of novel medications and technologies. The registry will include both children and adults, offering a unique opportunity to analyse the lifelong evolution of these rare diseases and complex conditions.
2. Healthcare providers (HCPs) in the field of rare uro-recto-genital diseases and complex conditions: The registry will have significant added value for all physicians involved in this field, where there are very few cases to create high-quality standards and EU guidelines. At the same time, the registry could represent a burden because of the time required to learn the platform and complete the datasets.  Crucially, without the collaboration of network HCPs, this registry will not succeed.  Therefore, HCPs are probably the most important target group.
3. Public health authorities and policymakers: The registry will be highly valuable to healthcare administrators at the local, regional, national, and EU levels, as it will generate novel information on disease epidemiology, management quality, and health outcomes that can be used for cost-efficiency analyses.
4. Researchers in the scientific community and the pharmaceutical industry: The registry will be very useful for both the pharmaceutical industry and independent academic researchers who need information on specific disease populations potentially suitable for involvement in clinical trials, epidemiological studies, and translational research.

In managing the ERN eUROGEN registry, different people have different roles as described in the protocol:
➡️ ERN eUROGEN Registry Protocol (version 3 July 2026)

• The Advisory Board (AB) consists of three ERN eUROGEN representatives and two European Patient Advocacy Group (ePAG) representatives who had an advisory role in setting up the ERN eUROGEN registry. Together with the Project Steering Committee, they will evaluate data application forms.
• The Coordinator (Dr. Loes van der Zanden) will help Principal Investigators with local implementation of the ERN eUROGEN registry. In addition, the Coordinator will further develop and maintain the ERN eUROGEN registry and ensure it stays up to date with international developments in registries. To qualify for funding, the registry coordinator reports registry progress to the European Commission.
• The Manager (Mw. Lotte Boormans) will enable data entry into the ERN eUROGEN registry by supporting participating Healthcare Providers and motivating continuous participation through useful data reports containing analysed results from the registry. In addition, the ERN eUROGEN registry Manager will guide the data sharing process and ensure that the ERN eUROGEN registry website is up to date. The ERN eUROGEN registry Manager will further develop the data elements to be collected in the ERN eUROGEN registry and will revise any sets of data elements when necessary, cumulating all encountered data registration issues and questions into Frequently Asked Questions documents. In addition, the ERN eUROGEN registry Manager will oversee data entry progress, perform data consistency evaluations, and inform Principal Investigators about inconsistencies to ensure the data in the ERN eUROGEN registry is of good quality.
• The Principal Investigators are responsible for the local implementation of the ERN eUROGEN registry at their Healthcare Provider. This includes obtaining approval from the ethics committee, the legal department, and the privacy officer, as well as ensuring that patients are asked for informed consent and that their data are entered into the ERN eUROGEN registry. The Principal Investigators are the main contact persons for the Coordinator and Manager.
• The Data Managers perform the data entry in the ERN eUROGEN registry. This could (but does not have to) be the same person as the Principal Investigator.
• The Scientific Researchers perform the planned analyses of diagnostic and treatment procedures using data collected from the ERN eUROGEN registry. This could be the same person as a Principal Investigator and/or a Data Manager.
• Applicants are stakeholders interested in using data collected from the ERN eUROGEN registry. This could be a Principal Investigator, a Data Manager and/or a Scientific Researcher, or another stakeholder. Other stakeholders don’t need to be affiliated with an ERN eUROGEN Healthcare Provider. The process of requesting and receiving data from the ERN eUROGEN registry is described in the data access and sharing policy:
  ➡️ ERN eUROGEN Registry Data Access and Sharing Policy (version 24 February 2025)

Radboudumc is the coordinator of the ERN eUROGEN registry. It has contracted with Castor EDC, a tradename of company Ciwit B.V. to allow the centralized storage of the Study Data. Given the fact that the Provider (the hospital participating in the ERN eUROGEN registry) and Radboudumc jointly developed and determined the purposes and means of the ERN eUROGEN registry, Parties shall be joint Controllers. However, Radboudumc, as the central Party that coordinates the ERN eUROGEN registry, shall be responsible for the storage and the use of the transferred data. Radboudumc shall ensure that appropriate technical and operational measures are in place to safeguard against any unauthorized or unlawful processing of the Study Data and against accidental loss or destruction. Radboudumc shall promptly, and in any event within 48 hours, notify the Provider about any actual or suspected breach of the Data Protection Legislation in relation to any Study Data.

The Provider is responsible to obtain and maintain any required ethical approval or similar necessary for the provision of Study Data to the ERN eUROGEN registry. In addition, the Provider is responsible for obtaining any required informed consent from each Data Subject before enrolling the respective Data Subject into the ERN eUROGEN registry and before transferring any data from that Data Subject. To that regard the Provider shall use the patient information and consent form as approved by its competent ethics committee. The consent shall cover inter alia the transfer of pseudonymized data (i.e. removing all sensitive personal data, including but not limited to patient names, initials, and other personally-identifiable information, and leaving only a coded Data Subject number) to Radboudumc and for use within the ERN eUROGEN registry and in scientific research projects approved in accordance with the Data Access and Sharing Policy;

Notwithstanding the division of responsibilities set out above, the Parties shall be jointly responsible for the compliance to obligations imposed by the Data Protection Legislation (Article 26 of the GDPR), and the Parties shall cooperate to do all necessary things to enable performance of such compliance obligations. Given the fact that Radboudumc will not have the key to the coded Study Data provided by Provider, The Parties agree that the Provider is primarily responsible for managing Data Subject requests exercising their rights under the GDPR and will comply with article 12 of the GDPR in order to respond to such a request. However, the Parties acknowledge that Data Subjects are allowed to exercise their rights under the GDPR against both Parties. If a Data Subject makes a request to Radboudumc, Radboudumc will notify the Provider about the request without undue delay. Radboudumc will assist Provider in complying with its obligation to provide an answer to Data Subject requests.